Order Article Reprints

Drevin G, Briet M, Bazzoli C, Gyan E, Schmidt A, Dombret H, Orvain C, Giltat A, Recher C, Ifrah N, et al. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics. 2022; 14(4):792. https://doi.org/10.3390/pharmaceutics14040792

Drevin, Guillaume, Marie Briet, Caroline Bazzoli, Emmanuel Gyan, Aline Schmidt, Hervé Dombret, Corentin Orvain, Aurelien Giltat, Christian Recher, Norbert Ifrah, and et al. 2022. "Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial" Pharmaceutics 14, no. 4: 792. https://doi.org/10.3390/pharmaceutics14040792

Drevin, G., Briet, M., Bazzoli, C., Gyan, E., Schmidt, A., Dombret, H., Orvain, C., Giltat, A., Recher, C., Ifrah, N., Guardiola, P., Hunault-Berger, M., & Abbara, C. (2022). Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics, 14(4), 792. https://doi.org/10.3390/pharmaceutics14040792